BCL2L11 and hepatocellular carcinoma: Foretinib, which is an oral multikinase inhibitor that inhibits c-Met, Recepteur d'origine nantais (RON; MST1R), the Gas6 tyrosine kinase receptor AXL and vascular endothelial growth factor receptor (VEGFR), improves overall survival in a preclinical model of hepatocellular carcinoma, through upregulation of Bim and p27 and downregulation of cyclin B1 and phosphorylated c-Myc [628].